Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: drsvelte who wrote (5510)	3/25/1998 10:07:00 AM
From: Hank	Read Replies (1) \| Respond to of 18691

I can't confirm this either. Until I do, I think it's BS.

To: drsvelte who wrote (5510)	3/25/1998 12:14:00 PM
From: Lazlo Pierce	Respond to of 18691

Found this on Yahoo <<Wednesday March 25, 10:27 am Eastern Time Company Press Release Zonagen Receives Lowrey Patent for Vasomax THE WOODLANDS, Texas--(BW HealthWire)--March 25, 1998--Zonagen, Inc. (NASDAQ:ZONA - news; PCX:ZNG) today announced that the U.S. Patent and Trademark Office has issued Patent Number 5,731,339 (the Lowrey Patent) for its proprietary formulation of Vasomax(TM), which was licensed worldwide to Schering-Plough Corporation (NYSE:SGP - news) in November 1997 for Male Erectile Dysfunction (MED). The Lowrey Patent describes new rapidly disintegrating oral formulations of phentolamine and methods of modulating human sexual response. The Lowrey patent also provides for an on-demand treatment for female sexual dysfunction. ''The Lowrey Patent further enhances Zonagen's proprietary position for Vasomax(TM) by providing both formulation and method-of-use coverage in the treatment of human sexual dysfunction,'' said Joseph S. Podolski, president and chief executive officer of Zonagen. In addition to the Lowrey patent, Zonagen also owns the rights to U.S. Patent Number 5,565,466 (the Zorgniotti Patent) which issued in October 1996. The Zorgniotti Patent is a broad method-of-use patent that provides for improved methods of modulating the human sexual response, in males and females, by administering certain vasodilators, including phentolamine, to the systemic circulation via certain non-invasive routes of administration. Zonagen, Inc. specializes in the development of products and services for management of reproductive health. The Company's technologies focus on the areas of urology, female health and contraception. Through its wholly owned subsidiary, Fertility Technologies, Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN.>> Dave